Mallinckrodt to Take Over Endo in Deal Valued at $6.7 Billion
Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo shareholders will receive a total of $80 million in cash and own nearly 50% of the combined company.
Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® ...
USA-based Endo Inc (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its international ...
Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally ...
We are headquartered at the Empire State Building in New York City and are investigating Endo, Inc. (OTC: NDOI), relating to the proposed merger with Mallinckrodt plc. Under the terms of the ...
The Ademi Firm is investigating Endo (OTCQX: NDOI) for possible breaches of fiduciary duty and other violations of law in its transaction with Mallinckrodt .
MALVERN, Pa., Feb. 17, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of its new branded television commercial, Steve's Journey. The campaign, featuring a real Dupuytren ...
March 13, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today reported financial results for the fourth quarter and full-year ended December 31, 2024. "We ended the ...
Endo, Inc. (OTCQX: NDOI) has announced a definitive agreement to divest its International Pharmaceuticals business, operated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback